Results 11 to 20 of about 1,067,293 (391)
HemaSphere, 2019 Acute myeloid leukemia (AML) occurs with a frequency of 3.5/1,000,000/year cases. AML patients have an invasion of diseased cells (blasts) medullary insufficiency, microenvironmental dysfunction, defects in the proliferation and function of the remaining
H. Döhner +2 more
semanticscholar +4 more sources
American Journal of Clinical Pathology, 2009 Myeloid sarcoma (MS), also termed extramedullary acute myeloid leukemia, extramedullary myeloid tumor, and granulocytic sarcoma or chloroma, is a rare manifestation that is characterized by the occurrence of 1 or more tumor myeloid masses occurring at an extramedullary site.
Campidelli C +3 more
openaire +3 more sources
Ontogeny of Myeloid Cells [PDF]
Frontiers in Immunology, 2014 Granulocytes, monocytes, macrophages, and dendritic cells (DCs) represent a subgroup of leukocytes, collectively called myeloid cells. During the embryonic development of mammalians, myelopoiesis occurs in a stepwise fashion that begins in the yolk sac and ends up in the bone marrow (BM).
Ismé de Kleer +4 more
openaire +7 more sources
Myeloid sarcoma as a manifestation of acute myeloid leukemia
Baylor University Medical Center Proceedings, 2021 We report a case of a 43-year-old man who presented with dyspnea because of large bilateral pleural effusions and imaging findings of a large periaortic mass with compression of the esophagus and left atrium. Subsequent soft tissue biopsy was consistent with myeloid sarcoma, and bone marrow biopsy was consistent with acute myeloid leukemia.
Lewis Woods, Jerry Fan, Hameed Ali
openaire +3 more sources
Cutaneous myeloid sarcoma associated with chronic myeloid leukemia [PDF]
Anais Brasileiros de Dermatologia, 2017 Myeloid sarcoma is an extramedullary tumor of malignant myeloid cells often associated with acute myeloid leukemia, chronic myeloproliferative disorders and myelodysplastic syndromes. The skin is one of the most commonly affected sites. We report a rare case of cutaneous myeloid sarcoma associated with chronic myeloid leukemia.
Vasconcelos, Erica Rodrigues de Araujo +2 more
openaire +6 more sources
Myeloid sarcoma in the tongue [PDF]
Autopsy and Case Reports, 2020 Leukemic cells are rarely present in the oral cavity, and there are very few reports regarding such cases. However, we identified some reports of leukemic cells infiltrating tissues in the oral cavity, including gingival involvement. Recurrent painful oral ulcerations and prominent generalized periodontal destruction are the most common oral features ...
Benites, Bernar Monteiro +5 more
openaire +4 more sources
Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia [PDF]
Frontiers in Oncology, 2015 The suppression of the immune system creates a permissive environment for development and progression of cancer. One population of immunosuppressive cells that have become the focus of intense study is myeloid derived suppressor cells (MDSCs), immature myeloid cells able to induce immune-escape, angiogenesis, and tumor progression.
Daniele Tibullo +7 more
openaire +6 more sources
EZH2 in Myeloid Malignancies [PDF]
Cells, 2020 Our understanding of the significance of epigenetic dysregulation in the pathogenesis of myeloid malignancies has greatly advanced in the past decade. Enhancer of Zeste Homolog 2 (EZH2) is the catalytic core component of the Polycomb Repressive Complex 2 (PRC2), which is responsible for gene silencing through trimethylation of H3K27. EZH2 dysregulation
Jenny Rinke +6 more
openaire +4 more sources
HoxA9 binds and represses the Cebpa +8 kb enhancer [PDF]
, 2019 C/EBPα plays a key role in specifying myeloid lineage development. HoxA9 is expressed in myeloid progenitors, with its level diminishing during myeloid maturation, and HOXA9 is over-expressed in a majority of acute myeloid leukemia cases, including those
Aplan, Peter D. +7 more
core +2 more sources
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
New England Journal of Medicine, 2020 BACKGROUND Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.
C. Dinardo +29 more
semanticscholar +1 more source